logo

Obseva Sa (OBSV)



Trade OBSV now with
  Date
  Headline
5/17/2022 1:06:11 AM ObsEva Q1 Net Loss $11.8 Mln Or $0.14/Shr Vs Loss $20.0 Mln Or $0.29/Shr Last Year
5/9/2022 1:06:18 AM ObsEva Presents Clinical Data On Oral GnRH Antagonist Linzagolix For Uterine Fibroids At The 2022 ACOG ACSM
5/2/2022 1:04:23 AM ObsEva Appoints Brandi Howard As Chief Clinical Officer, Effective May 9
4/25/2022 1:18:11 AM ObsEva: CHMP Of European Medicines Agency Confirms Positive Opinion For Linzagolix For Uterine Fibroids
3/22/2022 2:05:13 AM ObsEva Announces Addl Efficacy Results From Phase 3 EDELWEISS 3 Trial Of Linzagolix
2/1/2022 1:05:54 AM ObsEva Appoints Katja Buhrer As Chief Strategy Officer, Effective Feb. 1
1/6/2022 1:04:48 AM ObsEva Announces Positive Topline Results From Phase 3 EDELWEISS 3 Trial Of Linzagolix
12/17/2021 1:03:55 AM ObsEva Announces Positive CHMP Opinion For Linzagolix For Uterine Fibroids
12/10/2021 1:11:14 AM ObsEva Presents Clinical Data On Oral GnRH Antagonist Linzagolix At SEUD Congress 2021
11/22/2021 1:22:48 AM Obseva Appoints Stephanie Brown To Board
11/22/2021 1:15:39 AM Obseva: FDA Accepts NDA For Linzagolix For Management Of Heavy Menstrual Bleeding Associated With Uterine Fibroids